Yes / Aims/hypothesis Hypoglycaemia is a major barrier to good glucose control in type 1 diabetes. Frequent hypoglycaemic episodes impair awareness of subsequent hypoglycaemic bouts. Neural changes underpinning awareness of hypoglycaemia are poorly defined and molecular mechanisms by which glial cells contribute to hypoglycaemia sensing and glucose counterregulation require further investigation. The aim of the current study was to examine whether, and by what mechanism, human primary astrocyte (HPA) function was altered by acute and recurrent low glucose (RLG). Methods To test whether glia, specifically astrocytes, could detect changes in glucose, we utilised HPA and U373 astrocytoma cells and exposed them to RLG in vitro. This allowed measurement, with high specificity and sensitivity, of RLG-associated changes in cellular metabolism. We examined changes in protein phosphorylation/expression using western blotting. Metabolic function was assessed using a Seahorse extracellular flux analyser. Immunofluorescent imaging was used to examine cell morphology and enzymatic assays were used to measure lactate release, glycogen content, intracellular ATP and nucleotide ratios. Results AMP-activated protein kinase (AMPK) was activated over a pathophysiologically relevant glucose concentration range. RLG produced an increased dependency on fatty acid oxidation for basal mitochondrial metabolism and exhibited hallmarks of mitochondrial stress, including increased proton leak and reduced coupling efficiency. Relative to glucose availability, lactate release increased during low glucose but this was not modified by RLG. Basal glucose uptake was not modified by RLG and glycogen levels were similar in control and RLG-treated cells. Mitochondrial adaptations to RLG were partially recovered by maintaining euglycaemic levels of glucose following RLG exposure. Conclusions/interpretation Taken together, these data indicate that HPA mitochondria are altered following RLG, with a metabolic switch towards increased fatty acid oxidation, suggesting glial adaptations to RLG involve altered mitochondrial metabolism that could contribute to defective glucose counterregulation to hypoglycaemia in diabetes. / Diabetes UK (RD Lawrence Fellowship to CB; 13/0004647); the Medical Research Council (MR/N012763/1) to KLJE, ADR and CB; and a Mary Kinross Charitable Trust PhD studentship to CB, ADR and RW to support PGWP. Additional support for this work came from awards from the British Society for Neuroendocrinology (to CB and KLJE), the Society for Endocrinology (CB), Tenovus Scotland (CB) and the University of Exeter Medical School (CB and KLJE). AR was also supported by a Royal Society Industry Fellowship.

Many passerine birds, particularly corvids, are known to express complex cognitive skills comparable to those observed in primates. In order to examine how these similarities are reflected at the cellular level, I counted neurons and nonneuronal cells in passerine brains using the isotropic fractionator method. I show that, in these birds, neuronal numbers scale almost isometrically with telencephalic size, i.e., the average neuron size shows little increase and neuronal density decreases minimally as brains get larger. Neuronal densities in the passerine telencephalon exceed those observed in the primate cerebral cortex by a factor of 3-6. As a result, the number of telencephalic neurons in the Common Raven (Corvus corax) equals those observed in the cerebral cortex of small monkeys. The cerebellum features similar scaling rules. However, because the relative size of the cerebellum is smaller than in mammalian brains, cerebellar neurons make a much smaller proportion of total brain neurons than in mammals. In contrast to the little variation in neuronal densities in telencephalon and cerebellum, the density of neurons rapidly decreases with increasing structure size in the diencephalon, optic tectum and brain stem. For all examined brain structures, the densities of nonneuronal cells remain constant...

La capacité remarquable des neurones et des cellules gliales à migrer collectivement sur de longues distances assure l’architecture finale du cerveau. Ce processus est extrêmement dynamique et dépend non seulement de l’interaction entre les cellules mais aussi de la présence de facteurs de transcriptions spécifiques au sein de la cellule migrante. Les protéines d’adhésion comme les cadhérines et les chimioattractants/chimiorépulsifs sont connus pour réguler et guider la migration. Si le mode d’action de ces molécules a été extensivement étudié, les cascades de signalisation qui déclenchent le chimiotropisme sont loin d’être élucidées. Au cours de mon doctorat, j’ai analysé la régulation et le rôle d’un récepteur des chimioattractant au cours de la migration de la glie. Pour ceci j’ai utilisé le modèle du développement de la chaine gliale dans l’aile de la drosophile qui représente un outil de choix pour étudier les mécanismes moléculaires régulant la migration collective. / The remarkable ability of neurons and glia to undergo long distance and collective migration ensures the final architecture and function of the brain. This is an extremely dynamic process that not only depends on cell interactions, but also on the presence of specific transcription factors in the migrating cells. Adhesion molecules such as classic cadherins and chemoattractants/repellants are known to regulate directional migration, however, how are these pathways regulated is largely unknown. While the role of these molecules controlling cell interactions has been extensively investigated, the signaling cascades that trigger chemotropism are not understood. During the course of my PhD I have analyzed the role of an adhesion molecule and the impact of a chemoattractant receptor regulated by an early transcription factor in the process. The glial chain in a developing Drosophila wing provides an excellent tool to study the molecular pathway underlying collective migration.

No description available.

The Group III metabotropic glutamate receptors (mGluR) are located presynaptically on axon terminals and act as autoreceptors and heteroreceptors by inhibiting neurotransmitter release. Much has been learned about these receptors through exogenous application of L-serine-O-phosphate (L-SOP), an endogenous amino acid derivative and known activator of the Group III mGluRs. We hypothesized that L-SOP is the endogenous co-agonist at the high affinity Group III mGluR, mGluR4. We found the EC50 of L-SOP at mGluR4 was 0.5 μM, and determined that the concentration of L-SOP in whole brain was approximately 5 μM. An immunocytochemical survey revealed that cells containing the enzymatic machinery necessary for L-SOP synthesis and metabolism were observed in two brain regions known to express mGluR4, namely, cerebellum and hippocampus. In the cerebellum, the L-SOP synthetic and metabolic enzymes were found in Bergmann glia and Purkinje cells, two cells which form a tripartite synapse with parallel fiber axon terminals where the mGluR4 subtype is exclusively expressed at high levels. In the hippocampus, the L-SOP metabolic enzyme was detected in young neurons emanating from the neurogenic subventricular zone. Attempts to raise endogenous levels of L-SOP by crippling the L-SOP metabolizing enzyme (phosphoserine phosphatase), over-expressing the L-SOP synthesizing enzyme (phosphoserine aminotransferase), or through dietary protein restriction, to study the effects on neurotransmission and neurodevelopment in the central nervous system (CNS) were unsuccessful, suggesting that the production of L-SOP remains stable despite manipulation of the synthetic and metabolic enzymes. Finally, the ability of L-SOP to modulate glutamate release from presynaptic terminals was examined in cerebellar synaptosomes. Co-incident activation of presynaptic mGluR4 and presynaptic GABAA receptors facilitated glutamate release, suggesting that simultaneous activation of parallel fibers and Bergmann glia may serve to enhance synaptic transmission. This observation expands the traditional view of Group III mGluRs acting solely as inhibitory autoreceptors. Taken together, these results provide compelling evidence to support the hypothesis that L-SOP is the endogenous agonist at mGluR4, and possibly other Group III mGluRs.

The Group III metabotropic glutamate receptors (mGluR) are located presynaptically on axon terminals and act as autoreceptors and heteroreceptors by inhibiting neurotransmitter release. Much has been learned about these receptors through exogenous application of L-serine-O-phosphate (L-SOP), an endogenous amino acid derivative and known activator of the Group III mGluRs. We hypothesized that L-SOP is the endogenous co-agonist at the high affinity Group III mGluR, mGluR4. We found the EC50 of L-SOP at mGluR4 was 0.5 μM, and determined that the concentration of L-SOP in whole brain was approximately 5 μM. An immunocytochemical survey revealed that cells containing the enzymatic machinery necessary for L-SOP synthesis and metabolism were observed in two brain regions known to express mGluR4, namely, cerebellum and hippocampus. In the cerebellum, the L-SOP synthetic and metabolic enzymes were found in Bergmann glia and Purkinje cells, two cells which form a tripartite synapse with parallel fiber axon terminals where the mGluR4 subtype is exclusively expressed at high levels. In the hippocampus, the L-SOP metabolic enzyme was detected in young neurons emanating from the neurogenic subventricular zone. Attempts to raise endogenous levels of L-SOP by crippling the L-SOP metabolizing enzyme (phosphoserine phosphatase), over-expressing the L-SOP synthesizing enzyme (phosphoserine aminotransferase), or through dietary protein restriction, to study the effects on neurotransmission and neurodevelopment in the central nervous system (CNS) were unsuccessful, suggesting that the production of L-SOP remains stable despite manipulation of the synthetic and metabolic enzymes. Finally, the ability of L-SOP to modulate glutamate release from presynaptic terminals was examined in cerebellar synaptosomes. Co-incident activation of presynaptic mGluR4 and presynaptic GABAA receptors facilitated glutamate release, suggesting that simultaneous activation of parallel fibers and Bergmann glia may serve to enhance synaptic transmission. This observation expands the traditional view of Group III mGluRs acting solely as inhibitory autoreceptors. Taken together, these results provide compelling evidence to support the hypothesis that L-SOP is the endogenous agonist at mGluR4, and possibly other Group III mGluRs.

No description available.

The aim of this study was to investigate whether exercise could improve motor behavioral deficits and alter expression of glial fibrillary acidic protein (GFAP) in dorsal striatum in a 6-hydroxydopamine (6-OHDA) rat model of Parkinson’s disease (PD). To this end, animals were randomly divided into 4 groups: sham sedentary (SS, n = 7); sham trained (ST, n=8); lesioned sedentary (LS, n=8) and lesioned trained (LT, n = 8). Rats were unilaterally lesioned with 6-OHDA (10 μg/3 μg) injected into the left medial forebrain bundle and sham groups were only injected with vehicle solution. The treadmill training protocol consisted of running with progressive increase in velocity, 5 days/week, during 4 weeks. Behavioral tasks were applied to asses the motor abilities of all animals prior to 6-OHDA injection and at 8th and 29th days post-injection. The tyrosine hydroxylase (TH - in substantia nigra pars compacta) and GFAP (in dorsal striatum) immunostaining was evaluated by semiquantitative analysis of the intensity (optical density - OD). The 6-OHDA lesion decreased the OD of TH and increased the OD of GFAP. In addition, the 6-OHDA lesion increased the number of ipsilateral rotations induced by methylphenidate (40 mg/kg, i.p., 30 min) and caused motor behavioral deficits. On the other hand, the treadmill training resulted in an increase in maximal exercise capacity in both trained groups (ST and LT). The training was able to reduce the number of ipsilateral rotations and ameliorated the motor behavioral deficits on 8th and 29th days postlesion. Interestingly, the exercise led to a significant increase in OD of GFAP in the LT group while there was no such effect in ST group. Our results indicate that treadmill training can improve motor behavioral deficits and suggest that the effects of exercise may be directly or, indirectly, mediated by astrocytes, as an increase in GFAP was observed in the dorsal striatum. Nevertheless, these are the first data showing an increase in GFAP expression post-exercise in this model and further research is needed to determine the precise action of exercise on astrocytes in Parkinson’s disease.

The aim of this study was to investigate whether exercise could improve motor behavioral deficits and alter expression of glial fibrillary acidic protein (GFAP) in dorsal striatum in a 6-hydroxydopamine (6-OHDA) rat model of Parkinson’s disease (PD). To this end, animals were randomly divided into 4 groups: sham sedentary (SS, n = 7); sham trained (ST, n=8); lesioned sedentary (LS, n=8) and lesioned trained (LT, n = 8). Rats were unilaterally lesioned with 6-OHDA (10 μg/3 μg) injected into the left medial forebrain bundle and sham groups were only injected with vehicle solution. The treadmill training protocol consisted of running with progressive increase in velocity, 5 days/week, during 4 weeks. Behavioral tasks were applied to asses the motor abilities of all animals prior to 6-OHDA injection and at 8th and 29th days post-injection. The tyrosine hydroxylase (TH - in substantia nigra pars compacta) and GFAP (in dorsal striatum) immunostaining was evaluated by semiquantitative analysis of the intensity (optical density - OD). The 6-OHDA lesion decreased the OD of TH and increased the OD of GFAP. In addition, the 6-OHDA lesion increased the number of ipsilateral rotations induced by methylphenidate (40 mg/kg, i.p., 30 min) and caused motor behavioral deficits. On the other hand, the treadmill training resulted in an increase in maximal exercise capacity in both trained groups (ST and LT). The training was able to reduce the number of ipsilateral rotations and ameliorated the motor behavioral deficits on 8th and 29th days postlesion. Interestingly, the exercise led to a significant increase in OD of GFAP in the LT group while there was no such effect in ST group. Our results indicate that treadmill training can improve motor behavioral deficits and suggest that the effects of exercise may be directly or, indirectly, mediated by astrocytes, as an increase in GFAP was observed in the dorsal striatum. Nevertheless, these are the first data showing an increase in GFAP expression post-exercise in this model and further research is needed to determine the precise action of exercise on astrocytes in Parkinson’s disease.

Dissertação de Mestrado apresentada ao Programa de Pós-Graduação em Ciências da Saúde, da Universidade do Extremo Sul Catarinense - UNESC, para obtenção do título de mestre em Ciências da Saúde. / A meningite pneumocócica é uma infecção grave do sistema nervoso central (SNC), com altas taxas de letalidade, que provoca redução do desempenho psicomotor, ligeira lentidão mental, comprometimento das funções executivas de atenção e deficiência de aprendizagem e memória. O estabilizador de humor de lítio é conhecido como um agente neuroprotetor com muitos efeitos no cérebro. O tamoxifeno é a terapia endócrina usual para o câncer de mama. Pesquisas experimentais demonstraram que o tamoxifeno desempenha papéis neuroprotetores na lesão medular, hemorragia intracerebral, isquemia cerebral e lesão cerebral hipóxico-isquêmica. O objetivo deste estudo foi investigar os efeitos do lítio e do tamoxifeno sobre o fator neurotrófico derivado do cérebro (BDNF), fator neurotrófico derivado de célula da glia (GDNF) e fator de crescimento neuronal (NGF) no hipocampo de animais submetidos ao modelo experimental de meningite pneumocócica. Neste estudo, os animais receberam líquido cefalorraquidiano (LCR) artificial como um placebo ou uma suspensão de Streptococcus pneumoniae na concentração de 5 x 109 unidades formadoras de colônias (UFC/mL). Dezoito horas após a indução, todos os animais receberam ceftriaxona (100 mg/kg via intraperitoneal (i.p.) durante 7 dias). A partir do terceiro ao décimo dia os animais receberam solução salina, lítio (47,5 mg/kg) ou tamoxifeno (1 mg/kg) como tratamento adjuvante e foram separados em seis grupos: controle/salina, controle/lítio, controle/tamoxifeno, meningite/salina, meningite/lítio e meningite/tamoxifeno e foram submetidos aos testes comportamentais. No teste de habituação ao campo aberto, os animais submetidos à meningite não apresentaram diferença entre as sessões de treino e teste, demonstrando comprometimento da memória. Nos grupos controle/salina, controle/lítio, controle/tamoxifeno e meningite/lítio, houve diferença demonstrando memória de habituação nestes animais. Na tarefa de esquiva inibitória, houve diferença entre as sessões de treino e teste nos grupos controle/salina, controle/lítio, controle/tamoxifeno e meningite/lítio, demonstrando memória aversiva de curto e longo prazo nestes grupos. Nos grupos meningite/salina e meningite/tamoxifeno, não houve diferença entre as sessões de treino e teste, demonstrando comprometimento da memória aversiva a curto e longo prazo nestes animais. Após os testes os animais foram mortos e os hipocampos foram removidos para avaliação dos níveis de BDNF, NGF e GDNF. Os níveis de BDNF e GDNF foram restabelecidos no hipocampo dos animais tratados com lítio, no entanto, os níveis de BDNF, NGF e GDNF diminuíram no hipocampo de animais tratados com tamoxifeno. O lítio foi capaz de prevenir o comprometimento da memória e restabelecer a expressão de neurotrofinas no hipocampo em modelo experimental de meningite pneumocócica.